Wolfe Research initiated coverage of BioMarin (BMRN) with an Outperform rating and $95 price target With limited downside risk following recent share pullback, a new management team, and robust growth potential for lead asset Voxzogo , along with its legacy Enzyme Replacement Therapy business, the firm contends that there’s a lot to like about shares at current levels, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMRN:
- BioMarin initiated with an Outperform at Wolfe Research
- Biotech Alert: Searches spiking for these stocks today
- Alphabet upgraded, Boeing downgraded: Wall Street’s top analyst calls
- BioMarin price target lowered to $90 from $110 at Cantor Fitzgerald
- BioMarin price target raised to $106 from $104 at UBS